TCL1A is suggested to act as a coactivator of Akt, activator protein 1 (AP1), and NF-κB pathways with a potential involvement in CLL cells resistance to apoptotic mechanisms. Here, AKT1 is linked to B-cell chronic lymphocytic leukemia.